Browse > Article
http://dx.doi.org/10.3904/kjim.2011.26.3.304

Nuclear factor e2-related factor 2 Dependent Overexpression of Sulfiredoxin and Peroxiredoxin III in Human Lung Cancer  

Kim, Young-Sun (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine)
Lee, Hye-Lim (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine)
Lee, Ki-Bum (Department of Anatomical Pathology, Ajou University School of Medicine)
Park, Joo-Hun (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine)
Chung, Wou-Young (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine)
Lee, Keu-Sung (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine)
Sheen, Seung-Soo (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine)
Park, Kwang-Joo (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine)
Hwang, Sung-Chul (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine)
Publication Information
The Korean journal of internal medicine / v.26, no.3, 2011 , pp. 304-313 More about this Journal
Abstract
Background/Aims: Oxidative stress results in protein oxidation and is implicated in carcinogenesis. Sulfiredoxin (Srx) is responsible for the enzymatic reversal of inactivated peroxiredoxin (Prx). Nuclear factor E2-related factor 2 (Nrf2) binds to antioxidant responsive elements and upregulates the expression of Srx and Prx during oxidative stress. We aimed to elucidate the biological functions and potential roles of Srx in lung cancer. Methods: To study the roles of Srx and Prx III in lung cancer, we compared the protein levels of Nrf2, Prxs, thioredoxin, and Srx in 40 surgically resected human lung cancer tissues using immunoblot and immunohistochemical analyses. Transforming growth factor-${\beta}_1$, tumor necrosis factor-${\alpha}$, and camptothecin treatment were used to examine Prx III inactivation in Mv1Lu mink lung epithelial cells and A549 lung cancer cells. Results: Prx I and Prx III proteins were markedly overexpressed in lung cancer tissues. A significant increase in the oxidized form of a cysteine sulfhydryl at the catalytic site of Prxs was found in carcinogenic lung tissue compared to normal lung tissue. Densitometric analyses of immunoblot data revealed significant Srx expression, which was higher in squamous cell carcinoma tissue (60%, 12/20) than in adenocarcinoma (20%, 4/20). Also, Nrf2 was present in the nuclear compartment of cancer cells. Conclusions: Srx and Prx III proteins were markedly overexpressed in human squamous cell carcinoma, suggesting that these proteins may play a protective role against oxidative injury and compensate for the high rate of mitochondrial metabolism in lung cancer.
Keywords
GA-binding protein transcription factor; Peroxiredoxins; Sulfiredoxin; Lung neoplasms;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By SCOPUS : 0
연도 인용수 순위
1 Rhee SG. Cell signaling: H2O2, a necessary evil for cell signaling. Science 2006;312:1882-1883.   DOI   ScienceOn
2 Chowdhury I, Mo Y, Gao L, Kazi A, Fisher AB, Feinstein SI. Oxidant stress stimulates expression of the human peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant response element. Free Radic Biol Med 2009;46:146-153.   DOI   ScienceOn
3 Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 1998;273:6297-6302.   DOI   ScienceOn
4 Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 2005;11:571-578.   DOI   ScienceOn
5 Chang TS, Jeong W, Woo HA, Lee SM, Park S, Rhee SG. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 2004;279:50994-51001.   DOI   ScienceOn
6 Soriano FX, Baxter P, Murray LM, Sporn MB, Gillingwater TH, Hardingham GE. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells 2009;27:279-282.   DOI   ScienceOn
7 Woo HA, Jeong W, Chang TS, et al. Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. J Biol Chem 2005;280:3125-3128.   DOI
8 Hubner RH, Schwartz JD, De Bishnu P, et al. Coordinate control of expression of Nrf2-modulated genes in the human small airway epithelium is highly responsive to cigarette smoking. Mol Med 2009;15:203-219.   DOI   ScienceOn
9 Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008;2:351-374.   DOI   ScienceOn
10 Singh A, Ling G, Suhasini AN, et al. Nrf2-dependent sulfiredoxin-1 expression protects against cigarette smoke-induced oxidative stress in lungs. Free Radic Biol Med 2009;46:376-386.   DOI   ScienceOn
11 Shibata T, Kokubu A, Gotoh M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008;135:1358-1368.   DOI   ScienceOn
12 Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008;58:262-270.   DOI   ScienceOn
13 Lei K, Townsend DM, Tew KD. Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response. Oncogene 2008;27:4877-4887.   DOI   ScienceOn
14 Rhee SG, Jeong W, Chang TS, Woo HA. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int Suppl 2007;(106):S3-S8.
15 Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol 2003;23:8786-8794.   DOI   ScienceOn
16 Cho HY, Jedlicka AE, Reddy SP, et al. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002;26:175-182.   DOI   ScienceOn
17 Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116.   DOI   ScienceOn
18 Cho HY, Reddy SP, Kleeberger SR. Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal 2006;8:76-87.   DOI   ScienceOn
19 Colburn NH, Kensler TW. Targeting transcription factors for cancer prevention: the case of Nrf2. Cancer Prev Res (Phila) 2008;1:153-155.   DOI   ScienceOn
20 Kwak MK, Itoh K, Yamamoto M, Sutter TR, Kensler TW. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med 2001;7:135-145.
21 Stacy DR, Ely K, Massion PP, et al. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 2006;28:813-818.   DOI   ScienceOn
22 Kwak MK, Itoh K, Yamamoto M, Kensler TW. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 2002;22:2883-2892.   DOI   ScienceOn
23 Osburn WO, Kensler TW. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 2008;659:31-39.   DOI   ScienceOn
24 Park JJ, Chang HW, Jeong EJ, et al. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009;73:1196-1202.   DOI   ScienceOn
25 Park JH, Kim YS, Lee HL, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 2006;11:269-275.   DOI   ScienceOn
26 Bae SH, Woo HA, Sung SH, et al. Induction of sulfiredoxin via an Nrf2-dependent pathway and hyperoxidation of peroxiredoxin III in the lungs of mice exposed to hyperoxia. Antioxid Redox Signal 2009;11:937-948.   DOI   ScienceOn
27 Findlay VJ, Tapiero H, Townsend DM. Sulfiredoxin: a potential therapeutic agent? Biomed Pharmacother 2005;59:374-379.   DOI   ScienceOn
28 Jeong W, Park SJ, Chang TS, Lee DY, Rhee SG. Molecular mechanism of the reduction of cysteine sulfinic acid of peroxiredoxin to cysteine by mammalian sulfiredoxin. J Biol Chem 2006;281:14400-14407.   DOI   ScienceOn
29 Noh YH, Baek JY, Jeong W, Rhee SG, Chang TS. Sulfiredoxin translocation into mitochondria plays a crucial role in reducing hyperoxidized peroxiredoxin III. J Biol Chem 2009;284:8470-8477.   DOI